Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 27Triple Negative Breast Neoplasms 9Sarcoma 5Neoplasm Metastasis 4Liposarcoma 3Urinary Bladder Neoplasms 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Refractory Solid Tumors 1Recurrence 1Metastatic HER2-positive Breast Cancer 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1HER2-low Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Colorectal Neoplasms 1Brest Cancer 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Nivolumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 4Gemcitabine 4Cisplatin 4pembrolizumab 3cabozantinib 3avelumab 3Ipilimumab 3Carboplatin 3CTLA-4 Antigen 3enfortumab vedotin 2Immunoglobulin G 2Disulfides 2Biopsy 2tremelimumab 1trastuzumab deruxtecan 1tocilizumab 1tamibarotene 1relatlimab 1eribulin 1erdafitinib 1durvalumab 1atezolizumab 1Propranolol 1Platinum 1Leucovorin 1Lenalidomide 1Fluorouracil 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × eribulin × 1 year × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡